Literature DB >> 22426863

Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological long-term follow-up.

C A Jilg1, Hartmut P H Neumann, S Gläsker, O Schäfer, C Leiber, P U Ardelt, M Schwardt, W Schultze-Seemann.   

Abstract

We evaluated the clinicopathological outcome of von Hippel-Lindau (VHL)-patients who had mainly undergone nephron sparing surgery (NSS) for renal cell carcinoma (RCC) when the tumour diameter has reached 4.0 cm. Multiple, bilateral RCC with high recurrence rates and subsequent repeated interventions, followed by increasing risk for end-stage renal failure and metastases is characteristic for VHL. NSS is widely used for VHL-associated RCC at 3.0 cm cut-off. 54 VHL patients underwent NSS, nephrectomy or thermal ablation for RCC. We analysed time to second treatment, overall and cancer specific survival, intra- and post-operative data as well as tumour characteristics. We also examined the effects of delaying removal of RCC to 4.0 cm cut-off. Median follow-up was 67 months. 54 patients underwent 97 kidney treatments. 96 % of first and 67 % of second interventions comprised of NSS. 0 % metastases were observed in the group with largest tumour size ≤4 cm. The probability for second surgery was 21 %, at 5 years and 42 % at 10 years. Median time to second NSS was 149.6 months. The overall and cancer specific survival rate was 96.5 and 100 % at 5-year follow-up, and 82.5 and 90.5 % respectively at 10-year follow-up. Median delay to second NSS at 4.0 cm cut-off versus 3.0 cm was 27.8 months. NSS was both successfully used in first and second surgery and to some extent even in third surgery. By following a strict surveillance protocol it is possible to support a 4.0 cm-threshold strategy for NSS, based on the assumption that delaying time to second NSS prevents patients from premature renal failure.

Entities:  

Mesh:

Year:  2012        PMID: 22426863     DOI: 10.1007/s10689-012-9525-7

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  35 in total

1.  Oncological outcomes of partial nephrectomy for multifocal renal cell carcinoma greater than 4 cm.

Authors:  Gopal N Gupta; James Peterson; Kailash N Thakore; Peter A Pinto; W Marston Linehan; Gennady Bratslavsky
Journal:  J Urol       Date:  2010-05-15       Impact factor: 7.450

2.  Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter.

Authors:  Mesut Remzi; Mehmet Ozsoy; Hans-Christoph Klingler; Martin Susani; Matthias Waldert; Christian Seitz; Joerg Schmidbauer; Michael Marberger
Journal:  J Urol       Date:  2006-09       Impact factor: 7.450

3.  Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery.

Authors:  M M Walther; P L Choyke; G Glenn; J C Lyne; W Rayford; D Venzon; W M Linehan
Journal:  J Urol       Date:  1999-05       Impact factor: 7.450

4.  Growth kinetics in von Hippel-Lindau-associated renal cell carcinoma.

Authors:  C A Jilg; H P Neumann; S Gläsker; O Schäfer; P U Ardelt; M Schwardt; W Schultze-Seemann
Journal:  Urol Int       Date:  2011-12-09       Impact factor: 2.089

5.  Software and database for the analysis of mutations in the VHL gene.

Authors:  C Béroud; D Joly; C Gallou; F Staroz; M T Orfanelli; C Junien
Journal:  Nucleic Acids Res       Date:  1998-01-01       Impact factor: 16.971

6.  Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications.

Authors:  M M Walther; I A Lubensky; D Venzon; B Zbar; W M Linehan
Journal:  J Urol       Date:  1995-12       Impact factor: 7.450

7.  The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease.

Authors:  Branden G Duffey; Peter L Choyke; Gladys Glenn; Robert L Grubb; David Venzon; W Marston Linehan; McClellan M Walther
Journal:  J Urol       Date:  2004-07       Impact factor: 7.450

8.  Patterns of intervention for renal lesions in von Hippel-Lindau disease.

Authors:  Surena F Matin; Kamran Ahrar; Christopher G Wood; Molly Daniels; Eric Jonasch
Journal:  BJU Int       Date:  2008-05-15       Impact factor: 5.588

9.  Central nervous system lesions in von Hippel-Lindau syndrome.

Authors:  H P Neumann; H R Eggert; R Scheremet; M Schumacher; M Mohadjer; A K Wakhloo; B Volk; U Hettmannsperger; P Riegler; P Schollmeyer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

10.  Analysis of repeat nephron sparing surgery as a treatment option in patients with a solid mass in a renal remnant.

Authors:  James S Magera; Igor Frank; Christine M Lohse; Bradley C Leibovich; John C Cheville; Michael L Blute
Journal:  J Urol       Date:  2008-01-25       Impact factor: 7.450

View more
  9 in total

Review 1.  Renal cancer in von Hippel-Lindau disease and related syndromes.

Authors:  Birke Bausch; Cordula Jilg; Sven Gläsker; Alexander Vortmeyer; Niklas Lützen; Alexandra Anton; Charis Eng; Hartmut P H Neumann
Journal:  Nat Rev Nephrol       Date:  2013-07-30       Impact factor: 28.314

2.  Ischemia Techniques in Nephron-sparing Surgery: A Systematic Review and Meta-Analysis of Surgical, Oncological, and Functional Outcomes.

Authors:  Francesco Greco; Riccardo Autorino; Vincenzo Altieri; Steven Campbell; Vincenzo Ficarra; Inderbir Gill; Alexander Kutikov; Alex Mottrie; Vincenzo Mirone; Hendrik van Poppel
Journal:  Eur Urol       Date:  2018-10-13       Impact factor: 24.267

3.  Implications of Von Hippel-Lindau Syndrome and Renal Cell Carcinoma.

Authors:  Kenan Ashouri; Sophia Mohseni; John Tourtelot; Pranav Sharma; Philippe E Spiess
Journal:  J Kidney Cancer VHL       Date:  2015-09-25

Review 4.  Von Hippel-Lindau Disease: Current Challenges and Future Prospects.

Authors:  Sven Gläsker; Evelynn Vergauwen; Christian A Koch; Alexander Kutikov; Alexander O Vortmeyer
Journal:  Onco Targets Ther       Date:  2020-06-16       Impact factor: 4.147

5.  Hemangioblastoma Instead of Renal Cell Carcinoma Plays a Major Role in the Unfavorable Overall Survival of Von Hippel-Lindau Disease Patients.

Authors:  Bowen Zhou; Jiangyi Wang; Shengjie Liu; Xiang Peng; Baoan Hong; Jingcheng Zhou; Kaifang Ma; Jiufeng Zhang; Lin Cai; Kan Gong
Journal:  Front Oncol       Date:  2019-10-09       Impact factor: 6.244

6.  Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment.

Authors:  Jan-Helge Klingler; Sven Gläsker; Birke Bausch; Horst Urbach; Tobias Krauss; Cordula A Jilg; Christine Steiert; Alexander Puzik; Elke Neumann-Haefelin; Fruzsina Kotsis; Hansjürgen Agostini; Hartmut P H Neumann; Jürgen Beck
Journal:  Childs Nerv Syst       Date:  2020-06-07       Impact factor: 1.475

Review 7.  Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies.

Authors:  Emily Kim; Stefan Zschiedrich
Journal:  Front Pediatr       Date:  2018-02-09       Impact factor: 3.418

8.  A focused 35-minute whole body MRI screening protocol for patients with von Hippel-Lindau disease.

Authors:  Anne-Marie Vanbinst; Carola Brussaard; Evelynn Vergauwen; Vera Van Velthoven; Robert Kuijpers; Olaf Michel; Ina Foulon; Anna C Jansen; Bieke Lefevere; Susanne Bohler; Kathelijn Keymolen; Johan de Mey; Dirk Michielsen; Corina E Andreescu; Sven Gläsker
Journal:  Hered Cancer Clin Pract       Date:  2019-07-29       Impact factor: 2.857

9.  Growth characteristics and therapeutic decision markers in von Hippel-Lindau disease patients with renal cell carcinoma.

Authors:  Patrick Schuhmacher; Emily Kim; Felix Hahn; Peggy Sekula; Cordula Annette Jilg; Christian Leiber; Hartmut P Neumann; Wolfgang Schultze-Seemann; Gerd Walz; Stefan Zschiedrich
Journal:  Orphanet J Rare Dis       Date:  2019-10-28       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.